Found: 107
Select item for more details and to access through your institution.
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 5, p. 945, doi. 10.1007/s00432-018-2604-x
- By:
- Publication type:
- Article
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2013, v. 139, n. 12, p. 1985, doi. 10.1007/s00432-013-1529-7
- By:
- Publication type:
- Article
The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer.
- Published in:
- EMBO Molecular Medicine, 2019, v. 11, n. 11, p. N.PAG, doi. 10.15252/emmm.201910659
- By:
- Publication type:
- Article
Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance.
- Published in:
- Biologics: Targets & Therapy, 2008, v. 2, n. 2, p. 201
- By:
- Publication type:
- Article
Pevonedistat ( MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 4, p. 534, doi. 10.1111/bjh.13323
- By:
- Publication type:
- Article
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
- Published in:
- 2016
- By:
- Publication type:
- journal article
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non—Small-cell Lung Cancer: Is PD-Ll Expression a Good Marker for Patient Selection?
- Published in:
- Clinical Lung Cancer, 2016, v. 17, n. 5, p. 350, doi. 10.1016/j.cllc.2016.03.011
- By:
- Publication type:
- Article
ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma.
- Published in:
- PLoS ONE, 2012, v. 7, n. 1, p. 1, doi. 10.1371/journal.pone.0031120
- By:
- Publication type:
- Article
Is Personalized Medicine Here?
- Published in:
- Oncology (08909091), 2016, v. 30, n. 4, p. 293
- By:
- Publication type:
- Article
SLAM Modification as an Immune-Modulatory Therapeutic Approach in Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4808, doi. 10.3390/cancers15194808
- By:
- Publication type:
- Article
Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models.
- Published in:
- Cancers, 2019, v. 11, n. 7, p. 895, doi. 10.3390/cancers11070895
- By:
- Publication type:
- Article
Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model.
- Published in:
- Sarcoma, 2011, p. 1, doi. 10.1155/2011/130484
- By:
- Publication type:
- Article
Multidrug resistance protein expression in chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 1999, v. 86, n. 5, p. 805, doi. 10.1002/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E
- By:
- Publication type:
- Article
Comparison of technetium-99m sestamibi and indium-111 octreotide imaging in a patient with ewing's sarcoma before and after stem cell transplantation.
- Published in:
- Cancer (0008543X), 1997, v. 80, n. S12, p. 2478, doi. 10.1002/(SICI)1097-0142(19971215)80:12+<2478::AID-CNCR19>3.0.CO;2-9
- By:
- Publication type:
- Article
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-56461-4
- By:
- Publication type:
- Article
Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-55176-w
- By:
- Publication type:
- Article
Treatment of Acute Lymphoblastic Leukaemia: A New Era.
- Published in:
- Drugs, 2007, v. 67, n. 15, p. 2153, doi. 10.2165/00003495-200767150-00004
- By:
- Publication type:
- Article
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
- Published in:
- Journal of Cellular & Molecular Medicine, 2011, v. 15, n. 10, p. 2057, doi. 10.1111/j.1582-4934.2010.01218.x
- By:
- Publication type:
- Article
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
- Published in:
- Journal of Cellular & Molecular Medicine, 2010, v. 14, n. 10, p. 2448, doi. 10.1111/j.1582-4934.2009.00832.x
- By:
- Publication type:
- Article
Current and Emerging Treatment Options in Chronic Myeloid Leukemia.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 11, p. 2171, doi. 10.1002/cncr.22661
- By:
- Publication type:
- Article
Novel approaches in the treatment of systemic mastocytosis.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 7, p. 1429
- By:
- Publication type:
- Article
Secondary chromosomal abnormalities predict outcome in pediatric and adult high‐stage Burkitt lymphoma.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 5, p. 1084
- By:
- Publication type:
- Article
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 9, p. 1974
- By:
- Publication type:
- Article
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 7, p. 1569
- By:
- Publication type:
- Article
Proteomic‐based prediction of clinical behavior in adult acute lymphoblastic leukemiaAll participants provided written informed consent.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 7, p. 1587
- By:
- Publication type:
- Article
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 1, p. 120, doi. 10.1002/cncr.21595
- By:
- Publication type:
- Article
New approaches in the treatment of myelofibrosis.
- Published in:
- Cancer (0008543X), 2005, v. 103, n. 1, p. 32
- By:
- Publication type:
- Article
Author reply.
- Published in:
- Cancer (0008543X), 2004, v. 101, n. 6, p. 1478, doi. 10.1002/cncr.20496
- By:
- Publication type:
- Article
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies.
- Published in:
- Cancer (0008543X), 2004, v. 101, n. 5, p. 999
- By:
- Publication type:
- Article
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 12, p. 2583
- By:
- Publication type:
- Article
The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 10, p. 2167
- By:
- Publication type:
- Article
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 9, p. 1884, doi. 10.1002/cncr.20187
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 7, p. 1449
- By:
- Publication type:
- Article
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 4, p. 657, doi. 10.1002/cncr.20026
- By:
- Publication type:
- Article
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase.
- Published in:
- Cancer (0008543X), 2003, v. 98, n. 12, p. 2636
- By:
- Publication type:
- Article
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
- Published in:
- Cancer (0008543X), 2003, v. 98, n. 12, p. 2657
- By:
- Publication type:
- Article
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
- Published in:
- Cancer (0008543X), 2003, v. 98, n. 4, p. 773
- By:
- Publication type:
- Article
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
- Published in:
- Cancer (0008543X), 2003, v. 98, n. 3, p. 522
- By:
- Publication type:
- Article
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Treatment of Philadelphia chromosomepositive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside (Dr. Armand Keating served as guest editor for this article.).
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 12, p. 3010
- By:
- Publication type:
- Article
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 9, p. 2212, doi. 10.1002/cncr.11313
- By:
- Publication type:
- Article
Phase II study of SU5416a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitorin patients with refractory myeloproliferative diseases.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 8, p. 1920
- By:
- Publication type:
- Article
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophagecolony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 7, p. 1711, doi. 10.1002/cncr.11238
- By:
- Publication type:
- Article
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 5, p. 1248, doi. 10.1002/cncr.11217
- By:
- Publication type:
- Article
Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 4, p. 1033, doi. 10.1002/cncr.11223
- By:
- Publication type:
- Article
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
- Published in:
- Cancer (0008543X), 2002, v. 95, n. 9, p. 1923, doi. 10.1002/cncr.10900
- By:
- Publication type:
- Article
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
- Published in:
- 2002
- By:
- Publication type:
- journal article